Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Alkermes is positioned for growth in 2026, building on accomplishments from 2025 to enhance its value creation potential [3][5] - The company is characterized as a profitable neuroscience firm with a late-stage candidate, indicating a strong foundation for future development [5] Company Overview - Alkermes is participating in the 44th Annual Healthcare Conference, showcasing its management team and strategic direction [2] - The CEO, Richard Pops, expressed excitement about the company's trajectory and future opportunities [3] Financial and Strategic Position - The company emphasizes its strong foundation for both near-term and long-term growth, highlighting its profitability and leadership in the neuroscience sector [5]